Cargando…
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study
BRCA1/2 mutation carriers are offered gynaecological screening with the intention to reduce mortality by detecting ovarian cancer at an early stage. We examined compliance and efficacy of gynaecological screening in BRCA1/2 mutation carriers. In this multicentre, observational, follow-up study we ex...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360170/ https://www.ncbi.nlm.nih.gov/pubmed/17426707 http://dx.doi.org/10.1038/sj.bjc.6603725 |
_version_ | 1782152981696741376 |
---|---|
author | Hermsen, B B J Olivier, R I Verheijen, R H M van Beurden, M de Hullu, J A Massuger, L F Burger, C W Brekelmans, C T Mourits, M J de Bock, G H Gaarenstroom, K N van Boven, H H Mooij, T M Rookus, M A |
author_facet | Hermsen, B B J Olivier, R I Verheijen, R H M van Beurden, M de Hullu, J A Massuger, L F Burger, C W Brekelmans, C T Mourits, M J de Bock, G H Gaarenstroom, K N van Boven, H H Mooij, T M Rookus, M A |
author_sort | Hermsen, B B J |
collection | PubMed |
description | BRCA1/2 mutation carriers are offered gynaecological screening with the intention to reduce mortality by detecting ovarian cancer at an early stage. We examined compliance and efficacy of gynaecological screening in BRCA1/2 mutation carriers. In this multicentre, observational, follow-up study we examined medical record data of a consecutive series of 888 BRCA1/2 mutation carriers who started annual screening with transvaginal ultrasonography and serum CA125 between 1993 and 2005. The women were annually screened for 75% of their total period of follow-up. Compliance decreased with longer follow-up. Five of the 10 incident cancers were interval tumours, diagnosed in women with a normal screening result within 3–10 months before diagnosis. No difference in stage distribution between incident screen-detected and interval tumours was found. Eight of the 10 incident cancers were stage III/IV (80%). Cancers diagnosed in unscreened family members had a similar stage distribution (77% in stage III/IV). The observed number of cases detected during screening was not significantly higher than expected (Standardized Incidence Ratio (SIR): 1.5, 95% confidence interval: 0.7–2.8). For the subgroup that was fully compliant to annual screening, a similar SIR was found (1.6, 95% confidence interval: 0.5–3.6). Despite annual gynaecological screening, a high proportion of ovarian cancers in BRCA1/2 carriers are interval cancers and the large majority of all cancers are diagnosed in advanced stages. Therefore, it is unlikely that annual screening will reduce mortality from ovarian cancer in BRCA1/2 mutation carriers. |
format | Text |
id | pubmed-2360170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23601702009-09-10 No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study Hermsen, B B J Olivier, R I Verheijen, R H M van Beurden, M de Hullu, J A Massuger, L F Burger, C W Brekelmans, C T Mourits, M J de Bock, G H Gaarenstroom, K N van Boven, H H Mooij, T M Rookus, M A Br J Cancer Clinical Study BRCA1/2 mutation carriers are offered gynaecological screening with the intention to reduce mortality by detecting ovarian cancer at an early stage. We examined compliance and efficacy of gynaecological screening in BRCA1/2 mutation carriers. In this multicentre, observational, follow-up study we examined medical record data of a consecutive series of 888 BRCA1/2 mutation carriers who started annual screening with transvaginal ultrasonography and serum CA125 between 1993 and 2005. The women were annually screened for 75% of their total period of follow-up. Compliance decreased with longer follow-up. Five of the 10 incident cancers were interval tumours, diagnosed in women with a normal screening result within 3–10 months before diagnosis. No difference in stage distribution between incident screen-detected and interval tumours was found. Eight of the 10 incident cancers were stage III/IV (80%). Cancers diagnosed in unscreened family members had a similar stage distribution (77% in stage III/IV). The observed number of cases detected during screening was not significantly higher than expected (Standardized Incidence Ratio (SIR): 1.5, 95% confidence interval: 0.7–2.8). For the subgroup that was fully compliant to annual screening, a similar SIR was found (1.6, 95% confidence interval: 0.5–3.6). Despite annual gynaecological screening, a high proportion of ovarian cancers in BRCA1/2 carriers are interval cancers and the large majority of all cancers are diagnosed in advanced stages. Therefore, it is unlikely that annual screening will reduce mortality from ovarian cancer in BRCA1/2 mutation carriers. Nature Publishing Group 2007-05-07 2007-04-10 /pmc/articles/PMC2360170/ /pubmed/17426707 http://dx.doi.org/10.1038/sj.bjc.6603725 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Hermsen, B B J Olivier, R I Verheijen, R H M van Beurden, M de Hullu, J A Massuger, L F Burger, C W Brekelmans, C T Mourits, M J de Bock, G H Gaarenstroom, K N van Boven, H H Mooij, T M Rookus, M A No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
title | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
title_full | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
title_fullStr | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
title_full_unstemmed | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
title_short | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
title_sort | no efficacy of annual gynaecological screening in brca1/2 mutation carriers; an observational follow-up study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360170/ https://www.ncbi.nlm.nih.gov/pubmed/17426707 http://dx.doi.org/10.1038/sj.bjc.6603725 |
work_keys_str_mv | AT hermsenbbj noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT olivierri noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT verheijenrhm noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT vanbeurdenm noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT dehulluja noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT massugerlf noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT burgercw noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT brekelmansct noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT mouritsmj noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT debockgh noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT gaarenstroomkn noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT vanbovenhh noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT mooijtm noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy AT rookusma noefficacyofannualgynaecologicalscreeninginbrca12mutationcarriersanobservationalfollowupstudy |